How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rabeprazole-metronidazole-clarithromycin-amoxicillin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rabeprazole, metronidazole, Clarithromycin, Amoxicillin — Competitive Intelligence Brief

Rabeprazole, metronidazole, Clarithromycin, Amoxicillin (Rabeprazole, metronidazole, Clarithromycin, Amoxicillin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton pump inhibitor + antibiotic combination therapy. Area: Gastroenterology / Infectious Disease.

marketed Proton pump inhibitor + antibiotic combination therapy H+ ATPase (rabeprazole); bacterial ribosome and DNA (metronidazole, clarithromycin); bacterial cell wall (amoxicillin) Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Rabeprazole, metronidazole, Clarithromycin, Amoxicillin (Rabeprazole, metronidazole, Clarithromycin, Amoxicillin) — American University of Beirut Medical Center. This is a quadruple therapy combination that eradicates Helicobacter pylori by suppressing gastric acid and simultaneously attacking the bacteria with three antibiotics.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rabeprazole, metronidazole, Clarithromycin, Amoxicillin TARGET	Rabeprazole, metronidazole, Clarithromycin, Amoxicillin	American University of Beirut Medical Center	marketed	Proton pump inhibitor + antibiotic combination therapy	H+ ATPase (rabeprazole); bacterial ribosome and DNA (metronidazole, clarithromycin); bacterial cell wall (amoxicillin)
Omeprazole, Amoxicillin, Metronidazole and Clarithromycin	Omeprazole, Amoxicillin, Metronidazole and Clarithromycin	Al-Azhar University	marketed	Proton pump inhibitor + antibiotic combination therapy	H+ ATPase (omeprazole); bacterial ribosome and cell wall (amoxicillin, clarithromycin); bacterial DNA (metronidazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proton pump inhibitor + antibiotic combination therapy class)

Al-Azhar University · 1 drug in this class
American University of Beirut Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rabeprazole, metronidazole, Clarithromycin, Amoxicillin — Competitive Intelligence Brief. https://druglandscape.com/ci/rabeprazole-metronidazole-clarithromycin-amoxicillin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab